The Download: threats from space mirrors and credit for AI drugs
MIT Technology Review highlights emerging debates regarding intellectual property attribution and scientific credit for pharmaceuticals developed using artificial intelligence. As computational platforms take on greater roles in identifying and optimizing candidate molecules, life sciences organizations face growing ambiguity over patent inventorship requirements, balancing contributions between human researchers and generative design algorithms across drug discovery pipelines.